In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .
Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress.
There is little information about the hemodynamic and exercise-response implication s of renin-angiotensin system blocker combinations . After a 3-week lisinopril ( L ; 40 mg/day ) run-in , carvedilol ( C ; 20 then 40 mg/day ) or valsartan ( V ; 160 then 320 mg/day ) was added to L for 4 weeks each in a forced-titration , r and om order-entry crossover study in 30 subjects .  Arterial tonometry ( central pressures and time-tension index , TTI ) ; impedance cardiography ( steady-state hemodynamics ) , and ultrasound ( carotid flow )  were performed at rest and during supine bicycle exercise at 30 and 60 watts . At rest , both V and C lowered TTI similarly ( 7 % to 9 % , P = .05 compared with L , in part because they lowered blood pressure ( 3 to 7/3 to 4 mm Hg ) . V lowered central systolic pressure , augmentation pressure ( AP ) , and systemic vascular resistance ( SVR , all P < .02 ) ; C lowered heart rate but not central systolic pressure or SVR . During exercise , V persistently lowered central systolic pressure , AP , and SVR , whereas C did not . Neither drug affected exercise responses or carotid blood flow . Adding V or C to an angiotensin-converting enzyme inhibitor reduced cardiac workload by different mechanisms : vasodilation and reduced central blood pressure with V and lower heart rate with
In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .